ELISTAIR
8.6.2020 19:33:06 CEST | Business Wire | Press release
Elistair has announced the release of the Safe-T 2, their most advanced and powerful tethering system for use with commercially available drones. Key Features include IP54 rating, up to 125m / 400 feet micro-tether, 2 200 watts max continuous power, fiber optics option, and industry leading weight/power ratio from its patented Dynamic Voltage Optimization (DVO). The Safe-T 2 provides users with unmatched power efficiency and enables safe persistent flight time for UAVs .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005629/en/
SAFE-T 2 Video: https://youtu.be/9hBA41eDXHM
Since the launch of its first tethering station in 2015, Elistair has quickly become the industry leader in tethered drone systems with over 600 stations deployed to help security forces monitor events, secure sites, protect assets. The Safe-T 2 which has been built on the success of the Safe-T product line, deployed in over 60 countries by governmental organisations, industrial groups, and security forces will take tethering operations to a new level.
“To design the Safe-T 2, we worked in close collaboration with users who challenged us with their critical feedback. We rethought the entire solution to build the perfect tethering system for security operations.” Said Timothée PENET, Elistair Co-founder and CTO. “With up to 2,2 kW max continuous power and 2,8 kW peak power, it allows for higher flights with heavier payloads, thus enabling security forces to cover larger areas with a single system.”
Smart and Secured
The secure Dual-Comms option (Fiber optic and BPL), offers a redundant tethered data link or the possibility to select the best suited technology for the aircraft or payload. A patented Brake system allows the user to adapt the maximal tether length, depending on the safety zone needed, for instance in urban or crowded environments. Like its predecessor, the Safe-T 2 integrates Elistair’s live flight management system with T-monitor application offering optimal flight control for safer operations.
Ready for integration
Engineered to meet the most demanding missions with its rugged weather-resistant design, and compact modular metallic structure, the Safe-T 2 offers mounting plates and optional software development kit (SDK) for seamless integration into vehicles and fixed structures whilst also being agile enough for a single operator to deploy. Its interchangeable micro-tethers and smart adaptive winch control laws allow the operator to reconfigure the station and use the best tether weight/power range for each drone.
More information: www.elistair.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005629/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom